


Treatment Analysis Tool from Bayer Aids in Better Understanding of Healthcare Utilization in Colorectal Cancer

The treatment cost for colorectal cancer (CRC) patients in the U.S. is approximately \$14 billion a year and is projected to rise through 2020. As decision makers committed to improving patient outcomes, it is critical that you have the latest tools and technology that will help build a strong understanding of the trends in your own CRC and metastatic CRC (mCRC) populations. This includes patient characteristics, treatment patterns, and health resource utilization.

To help managed care professionals more effectively analyze medical and pharmacy claims, Bayer has developed the “Treatment and Analysis of Colorectal Cancer Evidence” (TRACE) Analyzer. The TRACE Analyzer is a software tool that collects all available claims information and provides valuable data including:

- Information on screening for CRC based on recommendations from the National Comprehensive Cancer Network (NCCN) Colorectal Cancer Screening Guideline
- Treatment adherence to guidelines
- Healthcare resource utilization
- Healthcare costs by line of therapy and NCCN listed status
- Population demographics and treatment duration
- Work-up tests according to NCCN Guidelines
- Treatment type
- Guideline-based treatment selection and medication utilization by line of therapy

The TRACE Analyzer is designed to help decision makers gain valuable insight into real-world treatment patterns and healthcare resource utilization to make informed assessments that are individualized to the patient population and health plan. The tool can also help identify opportunities for improving the quality of care and management of the CRC/mCRC population.



Sample output from TRACE

If you are interested in learning more, please contact NAMCP or Bayer Health Economics and Outcomes Researcher, Avin Yaldo at avin.yaldo@bayer.com.